Preparation and characterization of amphotericin B-loaded silk fibroin nanoparticles-in situ hydrogel composites for topical ophthalmic application
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Silk-based biomaterials and applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Ezisi CN, Ogbonnaya CE, Okoye O, Ezeanosike E, Ginger-Eke H, Arinze OC (2018) Microbial keratitis-a review of epidemiology, pathogenesis, ocular manifestations, and management. Niger J Ophthalmol 26:13–2310.4103/njo.njo_2_18 ↗
2. Mahmoudi S, Masoomi A, Ahmadikia K, Tabatabaei SA, Soleimani M, Rezaie S, Ghahvechian H, Banafsheafshan A (2018) Fungal keratitis: an overview of clinical and laboratory aspects. Mycoses 61(12):916–930. https://doi.org/10.1111/myc.1282210.1111/myc.12822 ↗
3. Ansari Z, Miller D, Galor A (2013) Current thoughts in fungal keratitis: diagnosis and treatment. Curr Fungal Infect Rep 7(3):209–218. https://doi.org/10.1007/s12281-013-0150-110.1007/s12281-013-0150-110.1007/s12281-013-0150-110.1007/s12281-013-0150-1 ↗
4. Austin A, Lietman T, Rose-Nussbaumer J (2017) Update on the management of infectious keratitis. Ophthalmology 124(11):1678–1689. https://doi.org/10.1016/j.ophtha.2017.05.01210.1016/j.ophtha.2017.05.012 ↗
5. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F (2021) Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther 10(1):115–147. https://doi.org/10.1007/s40121-020-00382-710.1007/s40121-020-00382-7 ↗
6. Chhonker YS, Prasad YD, Chandasana H, Vishvkarma A, Mitra K, Shukla PK, Bhatta RS (2015) Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol 72:1451–1458. https://doi.org/10.1016/j.ijbiomac.2014.10.01410.1016/j.ijbiomac.2014.10.014 ↗
7. Serrano DR, Ruiz-Saldaña HK, Molero G, Ballesteros MP, Torrado JJ (2012) A novel formulation of solubilised amphotericin B designed for ophthalmic use. Int J Pharm 437(1–2):80–82. https://doi.org/10.1016/j.ijpharm.2012.07.06510.1016/j.ijpharm.2012.07.065 ↗
8. Sharma A, Taniguchi J (2017) Review: emerging strategies for antimicrobial drug delivery to the ocular surface: Implications for infectious keratitis. Ocul Surf 15(4):670–679. https://doi.org/10.1016/j.jtos.2017.06.00110.1016/j.jtos.2017.06.001 ↗
9. Hartsel SC, Bauer E, Kwong EH, Wasan KM (2001) The effect of serum albumin on amphotericin B aggregate structure and activity. Pharm Res 18(9):1305–1309. https://doi.org/10.1023/a:101309001195210.1023/a:1013090011952 ↗
10. Adler-Moore JP, Proffitt RT (2008) Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 14(Suppl 4):25–36. https://doi.org/10.1111/j.1469-0691.2008.01979.x10.1111/j.1469-0691.2008.01979.x ↗
11. Patel A, Cholkar K, Agrahari V, Mitra AK (2013) Ocular drug delivery systems: an overview. World J Pharmacol 2(2):47–64. https://doi.org/10.5497/wjp.v2.i2.4710.5497/wjp.v2.i2.47 ↗
12. Tsai CH, Wang PY, Lin IC, Huang H, Liu GS, Tseng CL (2018) Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application. Int J Mol Sci 19(9):2830. https://doi.org/10.3390/ijms1909283010.3390/ijms19092830 ↗
13. Destruel P-L, Zeng N, Maury M, Mignet N, Boudy V (2017) In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond. Drug Discov 22(4):638–651. https://doi.org/10.1016/j.drudis.2016.12.00810.1016/j.drudis.2016.12.008 ↗
14. Das S, Suresh PK (2011) Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine: Nanotechnol Biol Med 7(2):242–247. https://doi.org/10.1016/j.nano.2010.07.00310.1016/j.nano.2010.07.003 ↗
15. Fu T, Yi J, Lv S, Zhang B (2017) Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. J Liposome Res 27(3):228–233. https://doi.org/10.1080/08982104.2016.122489910.1080/08982104.2016.1224899 ↗
16. Almeida H, Amaral MH, Lobão P, Lobo JMS (2014) In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov 19(4):400–412. https://doi.org/10.1016/j.drudis.2013.10.00110.1016/j.drudis.2013.10.001 ↗
17. Yang P, Dong Y, Huang D, Zhu C, Liu H, Pan X, Wu C (2019) Silk fibroin nanoparticles for enhanced bio-macromolecule delivery to the retina. Pharm Dev Technol 24(5):575–583. https://doi.org/10.1080/10837450.2018.154523610.1080/10837450.2018.1545236 ↗
18. Pham DT, Tiyaboonchai W (2020) Fibroin nanoparticles: a promising drug delivery system. Drug Deliv 27(1):431–448. https://doi.org/10.1080/10717544.2020.173620810.1080/10717544.2020.1736208 ↗
19. Chomchalao P, Nimtrakul P, Pham DT, Tiyaboonchai W (2020) Development of amphotericin B-loaded fibroin nanoparticles: a novel approach for topical ocular application. J Mater Sci 55(12):5268–5279. https://doi.org/10.1007/s10853-020-04350-x10.1007/s10853-020-04350-x ↗
20. Nikogeorgos N, Patil NJ, Zappone B, Lee S (2016) Interaction of porcine gastric mucin with various polycations and its influence on the boundary lubrication properties. Polymer 100:158–168. https://doi.org/10.1016/j.polymer.2016.08.03010.1016/j.polymer.2016.08.030 ↗
21. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51. https://doi.org/10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
22. Lynch C, Kondiah PPD, Choonara YE, du Toit LC, Ally N, Pillay V (2019) Advances in biodegradable nano-sized polymer-based ocular drug delivery. Polymers 11(8):1371. https://doi.org/10.3390/polym1108137110.3390/polym11081371 ↗
23. Zhang K, Shi X, Lin X, Yao C, Shen L, Feng Y (2015) Poloxamer-based in situ hydrogels for controlled delivery of hydrophilic macromolecules after intramuscular injection in rats. Drug Deliv 22(3):375–382. https://doi.org/10.3109/10717544.2014.89127210.3109/10717544.2014.891272 ↗
24. Al Khateb K, Ozhmukhametova EK, Mussin MN, Seilkhanov SK, Rakhypbekov TK, Lau WM, Khutoryanskiy VV (2016) In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery. Int J Pharm 502(1):70–79. https://doi.org/10.1016/j.ijpharm.2016.02.02710.1016/j.ijpharm.2016.02.027 ↗
25. Pham DT, Saelim N, Tiyaboonchai W (2018) Crosslinked fibroin nanoparticles using EDC or PEI for drug delivery: physicochemical properties, crystallinity and structure. J Mater Sci 53(20):14087–1410310.1007/s10853-018-2635-3 ↗
26. Lai C-F, Li J-S, Fang Y-T, Chien C-J, Lee C-H (2018) UV and blue-light anti-reflective structurally colored contact lenses based on a copolymer hydrogel with amorphous array nanostructures. RSC Adv 8(8):4006–4013. https://doi.org/10.1039/c7ra12753g10.1039/c7ra12753g ↗
27. Baranowski P, Karolewicz B, Gajda M, Pluta J (2014) Ophthalmic drug dosage forms: characterisation and research methods. Sci World J 2014:14. https://doi.org/10.1155/2014/86190410.1155/2014/861904 ↗
28. Almeida H, Amaral MH, Lobao P, Silva AC, Loboa JM (2014) Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. J Pharm Pharm Sci 17(3):278–293. https://doi.org/10.18433/j3dp4310.18433/j3dp43 ↗
29. Pham DT, Saelim N, Tiyaboonchai W (2019) Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy. Coll Surf B 181:705–713. https://doi.org/10.1016/j.colsurfb.2019.06.01110.1016/j.colsurfb.2019.06.011 ↗
30. Bhat NV, Nadiger GS (1980) Crystallinity in silk fibers: partial acid hydrolysis and related studies. J Appl Polym Sci 25(5):921–932. https://doi.org/10.1002/app.1980.07025051810.1002/app.1980.070250518 ↗
31. Irimia T, Ghica MV, Popa L, Anuţa V, Arsene A-L, Dinu-Pîrvu C-E (2018) Strategies for improving ocular drug bioavailability and corneal wound healing with chitosan-based delivery systems. Polymers 10(11):1221. https://doi.org/10.3390/polym1011122110.3390/polym10111221 ↗
32. Thoniyot P, Tan MJ, Karim AA, Young DJ, Loh XJ (2015) Nanoparticle-hydrogel composites: concept, design, and applications of these promising. Multi-Funct Mater Adv Sci 2(1–2):1400010. https://doi.org/10.1002/advs.20140001010.1002/advs.201400010 ↗
33. Argenta DbF, Santos TCd, Campos AM, Caon T (2019) Hydrogel nanocomposite systems: physicochemical characterization and application for drug-delivery systems, in nanocarriers for drug delivery: Nanoscience and nanotechnology in drug delivery. Elsevier In. 81–13110.1016/B978-0-12-814033-8.00003-5 ↗
34. Cabana A, Aït-Kadi A, Juhász J (1997) Study of the Gelation Process of Polyethylene Oxidea-Polypropylene Oxideb–Polyethylene OxideaCopolymer (Poloxamer 407) Aqueous Solutions. J Colloid Interface Sci 190(2):307–312. https://doi.org/10.1006/jcis.1997.488010.1006/jcis.1997.4880 ↗
35. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC (2006) A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 23(12):2709–2728. https://doi.org/10.1007/s11095-006-9104-410.1007/s11095-006-9104-4 ↗
36. Ruel-Gariépy E, Leroux J-C (2004) In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm 58(2):409–426. https://doi.org/10.1016/j.ejpb.2004.03.01910.1016/j.ejpb.2004.03.019 ↗
37. Jung Y-s, Park W, Park H, Lee D-K, Na K (2017) Thermo-sensitive injectable hydrogel based on the physical mixing of hyaluronic acid and Pluronic F-127 for sustained NSAID delivery. Carbohydr Polym 156(Supplement C) 156:403–408. https://doi.org/10.1016/j.carbpol.2016.08.06810.1016/j.carbpol.2016.08.068 ↗
38. Choi SW, Kim J (2018) Therapeutic contact lenses with polymeric vehicles for ocular drug delivery: a review. Materials (Basel) 11(7):1125. https://doi.org/10.3390/ma1107112510.3390/ma11071125 ↗
39. Lanier OL, Manfre MG, Bailey C, Liu Z, Sparks Z, Kulkarni S, Chauhan A (2021) Review of approaches for increasing ophthalmic bioavailability for eye drop formulations. AAPS PharmSciTech 22(3):1–16. https://doi.org/10.1208/s12249-021-01977-010.1208/s12249-021-01977-0 ↗
40. Kumar D, Jain N, Gulati N, Nagaich U (2013) Nanoparticles laden in situ gelling system for ocular drug targeting. J Adv Pharm Technol Res 4(1):9–17. https://doi.org/10.4103/2231-4040.10749510.4103/2231-4040.107495 ↗
41. Jain D, Kumar V, Singh S, Mullertz A, Bar-Shalom D (2016) Newer trends in in situ gelling systems for controlled ocular drug delivery. J Anal Pharm Res 2(3):1–1610.15406/japlr.2016.02.00022 ↗
42. El-Kamel AH (2002) In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm 241(1):47–55. https://doi.org/10.1016/S0378-5173(02)00234-X10.1016/S0378-5173(02)00234-X ↗
43. Morsi N, Ghorab D, Refai H, Teba H (2016) Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery. Int J Pharm 506(1):57–67. https://doi.org/10.1016/j.ijpharm.2016.04.02110.1016/j.ijpharm.2016.04.021 ↗
44. Wu C, Qi H, Chen W, Huang C, Su CC, Li W, Hou S (2007) Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi 127(1):183–19110.1248/yakushi.127.183 ↗
45. Shivam UU, Siddhi KC, Devarshi UG, Umeshkumar MU, Jayvadan KP (2020) Nanoparticles laden In situ gel for sustained drug release after topical ocular administration. J Drug Deliv Sci Technol 57:101736. https://doi.org/10.1016/j.jddst.2020.10173610.1016/j.jddst.2020.101736 ↗
46. Singh J, Chhabra G, Pathak K (2014) Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm 40:1223–123210.3109/03639045.2013.814061 ↗
47. Barwicz J, Christian S, Gruda I (1992) Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother 36(10):2310–2315. https://doi.org/10.1128/aac.36.10.231010.1128/aac.36.10.2310 ↗
48. Churchill DN, Seely J (1977) Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 19(3):176–181. https://doi.org/10.1159/00018088310.1159/000180883 ↗
49. Adams ML, Kwon GS (2003) Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block–poly(N-hexyl-l-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J Control Release 87(1):23–32. https://doi.org/10.1016/S0168-3659(02)00347-410.1016/S0168-3659(02)00347-4 ↗
50. Barwicz J, Tancrède P (1997) The effect of aggregation state of amphotericin-B on its interactions with cholesterol-or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids 85(2):145–155. https://doi.org/10.1016/S0009-3084(96)02652-710.1016/S0009-3084(96)02652-7 ↗
51. Zia Q, Khan AA, Swaleha Z, Owais M (2015) Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Int J Nanomedicine 10:1769–1790. https://doi.org/10.2147/ijn.s6315510.2147/ijn.s63155 ↗
52. Pham DT, Saelim N, Tiyaboonchai W (2019) Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy. Coll Surf B Biointerfaces 181:705–713. https://doi.org/10.1016/j.colsurfb.2019.06.01110.1016/j.colsurfb.2019.06.011 ↗